1Moellering RC. A novel antimicrobial agent joins the battle against resistant bacteria [ J ]. Ann Intern Med, 1999,130 ( 2 ) : 155-157.
2Shinabarger D. Mechanism of action of the oxazolidinone antibacte- rial agents [ J ]. Expert Opin Investig Drugs, 1999, 8 ( 8 ) : 1195- 1202.
3Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assess- ment of linezolid's clinical safety and tolerability: comparator-con- trolled phase III studies[ J]. Antimicrob Agents Chemother, 2003, 47(6) : 1824-1831.
4French G. Safety and tolerability of linezolid [ J ]. J Antimicrob Chemother, 2003, 51 ( Suppl 2) : ii45-ii53.
5Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid : summary of clinical experience [ J ]. Antimicrob Agents Chemother, 2002, 46(8): 2723-2726.
6Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for lin- ezolid-induced anemia and thrombocytopenia[ J]. Ann Pharmaco- ther, 2003, 37(4) : 517-520.
7Pascoalinho D, Vilas MJ, Coelho L, et al. Linezolid-related immune-mediated severe thrombocytopenia [ J]. Int J Antimicrob Agents, 2011, 37(1): 88-89.
9Senneville E, Legout L, Valette M, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis :a case-control study[ J ]. J Antimicrob Chemother, 2004, 54 (4) : 798 -802.
10Dawson M, Davis A, Elliott P, et al. Linezolid-induced dyseryth- ropoiesis: ehloramphenieol toxicity revisited [ J ]. Intern Med J, 2005, 35(10) : 6264528.
1Alamo ST,Kunutsor S,Walley J,et al.Performance of the new WHOdiagnostic algorithm for smear-negative pulmonary tuberculosis inHIV prevalent settings:a multisite study in Uganda[J].TropicalMedicine and International Health,2012,17(7):884-895.
